Drug Profile

Research programme: antibody based IgA degraders - Biohaven

Alternative Names: Anti-Gd-IgA-antibody; Anti-IgA antibody

Latest Information Update: 09 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biohaven Pharmaceuticals
Class Antibodies
Mechanism of Action Proteolysis

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical IgA nephropathy

Most Recent Events

31 May 2023 Preclinical trials in IgA nephropathy in USA (SC), prior to May 2023
31 May 2023 Biohaven Labs plans to file IND application for IgA nephropathy in 1H of 2024
31 May 2023 Pharmacodynamics data from a preclinical study in IgA nephropathy released by Biohaven Labs

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com